# LIPO (Lipella Pharmaceuticals Inc.) - SEC EDGAR Financial Statements

> Lipella Pharmaceuticals Inc. reported $390K in revenue and a net loss of $5.33M for the trailing twelve months ended September 30, 2025 (down 100.0% year over year), with a -1387.9% operating margin.

- Canonical: https://convexityos.com/fundamentals/LIPO
- Markdown: https://convexityos.com/fundamentals/LIPO.md
- SEC CIK: 0001347242
- Reporting currency: USD
- Latest filing period: September 30, 2025
- Last synced: Nov 21, 2026, 05:17 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001347242&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $390K | -100.0% YoY |
| Operating Income | TTM | -$5.41M | -1387.9% margin |
| Net Income | TTM | -$5.33M | -1367.4% net margin |
| Diluted EPS | TTM | -$1.17 | Split-adjusted |
| Free Cash Flow | TTM | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2025 | $1.86M | Total debt: $264K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- |
| **Revenue** | $536K | $450K | $184K | $259K |
| Research & Development | $3.61M | $3.04M | $2.55M | $1.46M |
| **Operating Income** | -$5.08M | -$4.75M | -$2.59M | -$1.92M |
| **EBITDA** | -$5.08M | -$4.74M | -$2.59M | -$1.92M |
| Interest Income | $64K | $138K | $1.7K | $104 |
| Interest Expense | -- | $11K | $9.6K | $6.8K |
| Income Before Tax | -$5.02M | -$4.62M | -$2.60M | -$1.87M |
| **Net Income** | -$5.02M | -$4.62M | -$2.60M | -$1.87M |
| Basic EPS | -$4.79 | -$6.16 | -$5.12 | -$4.40 |
| **Diluted EPS** | -$4.79 | -$6.16 | -$5.12 | -$4.40 |
| Basic Shares Outstanding | 1.0M | 750.4K | 507.6K | 426.0K |
| Diluted Shares Outstanding | 1.0M | 750.4K | 507.6K | 426.0K |

### Income Statement (Quarterly)

| Line Item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $87K | $129K | $174K | $80K | $136K | $146K | $121K |
| Research & Development | $721K | $792K | $993K | $1.06M | $1.05M | $662K | $843K | $454K |
| **Operating Income** | -$1.27M | -$1.36M | -$1.33M | -$1.45M | -$1.46M | -$952K | -$1.22M | -$730K |
| **EBITDA** | -$1.27M | -$1.36M | -$1.33M | -$1.45M | -$1.46M | -$951K | -$1.22M | -- |
| Interest Income | $20K | $29K | $21K | $9.6K | $15K | $14K | $26K | $41K |
| Interest Expense | -- | -- | -- | -- | -- | -- | -- | $0 |
| Income Before Tax | -$1.25M | -$1.33M | -$1.31M | -$1.44M | -$1.44M | -$938K | -$1.19M | -$689K |
| **Net Income** | -$1.25M | -$1.33M | -$1.31M | -$1.44M | -$1.44M | -$938K | -$1.19M | -$689K |
| Basic EPS | -$0.28 | -$0.31 | -$0.64 | -- | -$1.29 | -$0.99 | -$1.31 | -- |
| **Diluted EPS** | -$0.28 | -$0.31 | -$0.64 | -- | -$1.29 | -$0.99 | -$1.31 | -- |
| Basic Shares Outstanding | 4.5M | 4.3M | 2.1M | -- | 1.1M | 950.7K | 911.5K | -- |
| Diluted Shares Outstanding | 4.5M | 4.3M | 2.1M | -- | 1.1M | 950.7K | 911.5K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $2.18M | $3.29M | $5.12M | $1.41M |
| Short-Term Investments | -- | -- | -- | $301K |
| **Cash & Short-Term Investments** | $2.18M | $3.29M | $5.12M | $1.71M |
| Accounts Receivable, Net | $85K | $32K | $114K | -- |
| **Total Current Assets** | $2.62M | $3.43M | $5.80M | $1.81M |
| Property, Plant & Equipment, Net | $9.9K | $13K | -- | -- |
| **Total Non-Current Assets** | $57K | $148K | $151K | $205K |
| **Total Assets** | $2.67M | $3.58M | $5.95M | $2.01M |
| Accounts Payable | $388K | $138K | $384K | $47K |
| Other Current Liabilities | -- | -- | $250K | $25K |
| **Total Current Liabilities** | $754K | $385K | $1.18M | $341K |
| Other Non-Current Liabilities | -- | -- | -- | $50K |
| **Total Non-Current Liabilities** | $0 | $47K | $96K | $249K |
| **Total Liabilities** | $754K | $433K | $1.27M | $589K |
| **Total Debt (incl. Leases)** | $48K | $137K | $155K | $208K |
| Common Stock | $121 | $75 | $574 | $387 |
| Retained Earnings | -$15.34M | -$10.32M | -$5.70M | -$3.11M |
| **Total Stockholders' Equity** | $1.92M | $3.14M | $4.68M | $1.42M |
| Total Equity | $1.92M | $3.14M | $4.68M | $1.42M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $1.86M | $2.78M | $4.23M | $2.18M | $1.35M | $1.19M | $2.11M | $3.29M |
| **Cash & Short-Term Investments** | $1.86M | $2.78M | $4.23M | $2.18M | $1.35M | $1.19M | $2.11M | $3.29M |
| Accounts Receivable, Net | -- | -- | -- | $85K | $31K | $35K | $69K | $32K |
| **Total Current Assets** | $2.08M | $3.44M | $4.82M | $2.62M | $2.08M | $2.08M | $3.01M | $3.43M |
| Property, Plant & Equipment, Net | $7.7K | $8.4K | $9.1K | $9.9K | $11K | $11K | $12K | $13K |
| **Total Non-Current Assets** | $271K | $283K | $33K | $57K | $80K | $103K | $126K | $148K |
| **Total Assets** | $2.35M | $3.72M | $4.86M | $2.67M | $2.16M | $2.18M | $3.14M | $3.58M |
| Accounts Payable | $463K | $608K | $392K | $388K | $459K | $178K | $294K | $138K |
| **Total Current Liabilities** | $642K | $747K | $777K | $754K | $701K | $480K | $552K | $385K |
| **Total Non-Current Liabilities** | $220K | $232K | $1 | $0 | $0 | $0 | $24K | $47K |
| **Total Liabilities** | $862K | $979K | $777K | $754K | $701K | $480K | $576K | $433K |
| **Total Debt (incl. Leases)** | $264K | $275K | $24K | $48K | $71K | $94K | $24K | $137K |
| Common Stock | $462 | $446 | $254 | $121 | $109 | $761 | $704 | $75 |
| Retained Earnings | -$19.23M | -$17.97M | -$16.65M | -$15.34M | -$13.90M | -$12.45M | -$11.52M | -$10.32M |
| **Total Stockholders' Equity** | $1.49M | $2.74M | $4.08M | $1.92M | $1.46M | $1.70M | $2.56M | $3.14M |
| Total Equity | $1.49M | $2.74M | $4.08M | $1.92M | $1.46M | $1.70M | $2.56M | $3.14M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- |
| Net Income | -$5.02M | -$4.62M | -$2.60M | -$1.87M |
| Depreciation & Amortization | $2.9K | $1.7K | $0 | $0 |
| Change in Payables | $250K | -$246K | $337K | $22K |
| **Operating Cash Flow** | -$3.95M | -$3.15M | -$1.83M | -$989K |
| Capital Expenditure | -- | -$14K | -- | -- |
| **Free Cash Flow** | -- | -$3.16M | -- | -- |
| **Investing Cash Flow** | -- | -$14K | $301K | -$301K |
| Common Stock Issued | -- | -- | $4.96M | $2.10M |
| **Financing Cash Flow** | $2.84M | $1.34M | $5.24M | $2.10M |
| **Net Change in Cash** | -$1.11M | -$1.83M | $3.71M | $807K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.25M | -$1.33M | -$1.31M | -$1.44M | -$1.44M | -$938K | -$1.19M | -$689K |
| Depreciation & Amortization | $722 | $721 | $722 | $721 | $722 | $722 | $721 | -- |
| Change in Payables | -$145K | $216K | $3.9K | -$71K | $281K | -$115K | $156K | -$165K |
| **Operating Cash Flow** | -$926K | -$1.43M | -$1.43M | -$990K | -$653K | -$919K | -$1.39M | -$728K |
| Common Stock Issued | $0 | -$10K | $3.47M | -- | $820K | $0 | $200K | -- |
| **Financing Cash Flow** | $0 | -$10K | $3.47M | $1.82M | $820K | $0 | $200K | $1.61M |
| **Net Change in Cash** | -$926K | -$1.44M | $2.04M | $831K | $167K | -$919K | -$1.19M | $884K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- |
| **Operating Margin** | -947.2% | -1055.6% | -1406.3% | -738.7% |
| **Net Profit Margin** | -935.2% | -1027.3% | -1410.6% | -719.3% |
| Return on Equity (ROE) | -261.3% | -146.9% | -55.6% | -131.0% |
| Return on Assets (ROA) | -187.6% | -129.1% | -43.7% | -92.7% |
| Current Ratio | 3.47x | 8.90x | 4.92x | 5.31x |
| Quick Ratio | 3.01x | 8.63x | 4.44x | 5.03x |
| Debt to Equity | 0.02x | 0.04x | 0.03x | 0.15x |
| **Revenue Growth (YoY)** | +19.3% | +144.2% | -29.0% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -1387.9% | -1190.0% | -998.5% | -947.2% | -901.5% | -839.1% | -1021.9% | -1055.6% |
| **Net Profit Margin** | -1367.4% | -1174.1% | -987.0% | -935.2% | -881.7% | -816.7% | -993.4% | -1027.3% |
| Return on Equity (ROE) | -358.3% | -201.3% | -125.8% | -261.3% | -292.2% | -243.1% | -185.2% | -146.9% |
| Return on Assets (ROA) | -226.8% | -148.4% | -105.7% | -187.6% | -197.4% | -189.7% | -151.2% | -129.1% |
| Current Ratio | 3.24x | 4.60x | 6.21x | 3.47x | 2.97x | 4.33x | 5.46x | 8.90x |
| Quick Ratio | 2.89x | 3.72x | 5.44x | 3.01x | 1.97x | 2.54x | 3.94x | 8.63x |
| Debt to Equity | 0.18x | 0.10x | 0.01x | 0.02x | 0.05x | 0.05x | 0.01x | 0.04x |
| **Revenue Growth (YoY)** | -100.0% | -36.4% | -11.3% | +43.7% | -22.7% | +27.9% | +23.6% | -20.0% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
